ChenYe

Associate

Silicon Valley + 1.650.687.4189

Connect:

Share

Chen Ye represents public and private companies in securities offerings, SEC compliance, domestic and cross-border financing and M&A transactions, restructurings, and other general corporate governance matters. She has advised clients in a variety of industries, including e-commerce, semiconductors, media and social media, education, tourism, banking, jewelry, gaming, retail, mining, oil and gas, and manufacturing.

In addition, Chen actively participates in national and local organizations promoting better communication and understanding of U.S. and Chinese laws and cultures. Chen is fluent in Mandarin and previously practiced in the New York, Menlo Park, and Hong Kong offices of international law firms.

Experience

  • QuickLogic completes public offering of Common StockJones Day represented QuickLogic Corporation, a developer of ultra-low power multi-core voice enabled SoCs, embedded FPGA IP, and Endpoint AI solutions, in connection with the underwritten public offering of Common Stock.
  • GenScript Biotech Corporation completes US$423.8 million IPO and spin-off of its subsidiary Legend Biotech Corporation; and US$24 million purchase of Ordinary Shares of Legend BiotechJones Day acted as the U.S. and Hong Kong legal advisors of GenScript Biotech Corporation (“GenScript Biotech”) in relation to its (a) approximately US$423.8 million initial public offering of 18,425,000 American Depositary Shares and spin-off listing of its subsidiary Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”) on the Nasdaq Global Select Market and (b) approximately US$24 million purchase of Ordinary Shares of Legend Biotech in a concurrent private placement of Legend Biotech.
  • LDV Partners Fund II invests in CompilerWorks, Inc.Jones Day represented LDV Partners Fund II, L.P. in connection with its Series A investment in CompilerWorks, Inc., a Silicon Valley-based startup focused on transpiler and lineage solutions.
  • Synaptics divests LCD TDDI business to Hua Capital for $139.4 millionJones Day advised Synaptics Incorporated in its $139.4 million divestiture of its Asia-based mobile LCD TDDI Business to an affiliate of Hua Capital.
  • Benitec Biopharma redomiciled to U.S.Jones Day advised Benitec Biopharma Limited (ASX and NASDAQ listed) ("Benitec Australia") in its redomiciliation from Australia to the U.S. pursuant to a statutory scheme of arrangement under Australian law (the "Scheme").
  • YETI Holdings completes $333.5 million secondary offering of Common StockJones Day represented YETI Holdings, Inc., a designer, marketer, retailer, and distributor of a variety of innovative, branded, premium products, in connection with the $333.5 million underwritten secondary public offering of 11,500,000 shares of Common Stock by certain of its stockholders.
  • QuickLogic completes $9.2 million public offering of Common StockJones Day represented QuickLogic Corporation, a developer of ultra-low power multi-core voice enabled SoCs, embedded FPGA IP, and Endpoint AI solutions, in connection with a $9.2 million underwritten public offering of 18,400,000 total shares of Common Stock.
  • Chroma acquires 20.5% of CamtekJones Day advised Chroma ATE Inc., a leading Taiwanese corporation, in its acquisition of approximately 20.5% of the shares of Camtek Ltd. at $9.50 per share.
  • Huadong Medicine invests in R2 Dermatology and enters into distribution agreementJones Day advised Huadong Medicine Co. Ltd., a Chinese manufacturer and distributor of pharmaceutical and other medical products, in connection with its subscription of Series B Preferred Shares of R2 Dermatology, Inc., and the negotiation of a distribution agreement authorizing Huadong Medicine as an exclusive distributor in Asia for R2's skin whitening products.
  • Goldman Sachs provides credit facility to CredijustoJones Day represented Goldman Sachs in connection with a credit facility provided to Credijusto, a Mexican financial technology firm.
  • QuickLogic acquires SensiML CorporationJones Day advised QuickLogic Corporation, a developer of ultra-low power multi-core voice-enabled SoCs, embedded FPGA IP, and Endpoint AI solutions, in its acquisition of SensiML Corporation.
  • RPS Ventures I, L.P. forms fund to invest in high-growth technology opportunitiesJones Day represented RPS Ventures I, L.P. in connection with the formation of a fund to invest in high-growth technology opportunities.
  • Itron acquires Silver Spring Networks for $830 million, net of $118 million of Silver Spring's cashJones Day advised Itron, Inc. (NASDAQ: ITRI) in its acquisition of Silver Spring Networks, Inc. (NYSE: SSNI) by acquiring all outstanding shares of Silver Spring Networks, Inc. (NYSE: SSNI) for $16.25 per share in cash.
  • Athyrium Capital Management invests in Village Practice Management Company via notes and warrantsJones Day advised Athyrium Capital Management, LP in connection with its investment in Village Practice Management Company, LLC, a venture stage healthcare and technology company that partners with primary care providers to facilitate their shift from volume-based to value-based compensation models, of up to $80 million of Senior Secured Notes with warrants in a private placement.
  • Bison Capital acquires majority of outstanding Class A Common Stock in CinedigmJones Day represented Bison Capital Holding Company Limited in connection with its acquisition of a majority of the outstanding Class A Common Stock in Cinedigm Corp., a leading independent content distributor.
  • Peterson Partners completes $21.1 million follow-on global offering by selling shareholders of AzulJones Day represented Peterson Partners, manager of Maracatu, LLC, in the follow-on global offering of preferred shares by the selling shareholders of Azul S.A., a provider of airline passenger and cargo services located in Brazil.
    • View All

    October 2018 Commentaries

    California Mandates Female Directors for Public Corporations
    We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.